Tozaro has announced the appointment of Dr Jason Slingsby as Chief Executive Officer.
Jason will lead the company’s long-term strategy, including commercialisation of its Smart Polymer technology to enhance downstream manufacturing of viral vectors in cell and gene therapy (CGT).
A renowned biotech leader, Jason has over 20 years of experience and demonstrated successes in business development, strategic partnering, M&A, fundraising and establishing and managing significant commercial relationships.
He will lead Tozaro as it capitalises on early momentum following the company’s transition to the CGT bioprocessing sector in August 2024, since which time Guy Leaver, board member, has been acting as interim CEO.
Prior to joining Tozaro, Jason was chief business officer for LifeArc, where he led all business development, alliance management, IP, funding and technology transfer functions.
Before this, he was chief business and corporate development officer at OXB (previously Oxford Biomedica), a leading viral vector CDMO, where he guided the company’s M&A and strategic partnering efforts, including significant expansion into the US market.
As CEO and co-founder of ProtAffin AG, a clinical-stage spin-out, he secured more than £20m in funding to develop novel biologics.
Jason said: “Tozaro is an exciting company in the cell and gene therapy manufacturing technology space, and I look forward to working with the team, and with Michele as the new chair, to continue to build value, forge new partnerships and strengthen our position as innovators.”
